Loading CompoundSearch
Growth-hormone-releasing peptides like CJC-1295, Ipamorelin, and Sermorelin, studied for stimulating the body's own GH secretion.
Growth hormone peptides split into two real families that work differently: GHRH analogs (Sermorelin, CJC-1295, Tesamorelin) prep and refill your pituitary's own GH supply, while GHRPs/ghrelin mimetics (Ipamorelin, GHRP-2, GHRP-6, Hexarelin) trigger the actual release pulse. Most serious protocols pair one from each rather than doubling up on either side, since the two work through completely different mechanisms rather than competing for the same one. Bloodwork before and during a protocol is the most reliable way to track what's actually changing — diet and training move body composition just as much as any peptide does, so it's easy to misattribute results to the wrong variable. Anyone with existing diabetes, insulin resistance, a family history of metabolic disorders, or without recent bloodwork should be extra cautious, since GH secretagogues can meaningfully affect blood sugar.
Looking for something specific, or placing a wholesale order? Send us a DM or email.
Looking for something else? Browse all compounds
Exogenous GH (somatropin/HGH) and GH secretagogues aren't equivalent, even though both raise GH/IGF-1 activity. HGH delivers recombinant growth hormone directly, bypassing your pituitary and creating a non-physiological, more continuous elevation — which also creates negative feedback that can suppress your pituitary's own GH production.
Secretagogues (GHRH analogs like Sermorelin or Tesamorelin, ghrelin mimetics like Ipamorelin, or combinations) stimulate your pituitary to release your own GH in a more natural, pulsatile pattern, with your body's own regulatory brake (somatostatin) staying at least partially intact. That's the main reason secretagogues are generally viewed as milder at typical doses.
Not mandatory in a legal sense, but genuinely important practically. Results from any GH secretagogue are hard to separate from diet and training, both of which move body composition just as much as the peptide does — bloodwork is the only real way to confirm what's actually changing rather than guessing.
The category splits into two real sub-groups that work differently: GHRPs act on the ghrelin/GHS-R1a receptor (GHRP-6, GHRP-2, Ipamorelin), while GHRH analogs act on the growth-hormone-releasing-hormone receptor (Sermorelin, CJC-1295, Tesamorelin). Both aim to raise natural growth hormone, but through different mechanisms with different side-effect profiles — understanding which is which helps you ask better questions and avoid mixing up the two during research.
People with existing diabetes or insulin resistance, anyone with a family history of metabolic disorders, people on medications that affect blood sugar, and anyone without recent bloodwork or a primary care relationship. GH secretagogues can meaningfully affect blood sugar, so this isn't a minor caveat.
Because together they create a synergistic release far bigger than either one alone. GHRH preps and fills the pituitary with stored growth hormone, and GHRP triggers the pulse that releases it. Because they work through different cellular pathways, they don't compete with each other — they multiply the output instead.